Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Mugsy, I am more accurate than you.

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jul 26, 2022 12:29pm

81 Views

Post# 34851288

RE:RE:Mugsy, I am more accurate than you.

Inthepez wrote:

Stutters wrote: Plain and simple

also stutters for brains: ate up $ 2.82 or 587% Guess my friday info was correct.

lmao! Great call there, chump.

Thanks Pez ... love that I'm top-of-mind for some of those dirt bags.
Bet they'd love to hold my picture up - with one hand.
Hahaha !

Stole that from Steve Martin

--------------

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing